Emissions reduction fuel technology developer Quadrise (LON: QED) had cash of £4m at the end of 2025 having lost £2m in the first half. The MSC vessel and OCP (Morocco) trials are being prepared and there are talks with other ship owners. The share price increased 15.85 to 1.7375p.
Strategic Minerals (LON: SML) will publish a new mineral resource estimate for the Redmoor tungsten tin copper project on Thursday 26 March. There will also be an updated Economic Sensitivity Analysis. The share price rose a further 11% to 6.05p, which is the highest it has been for 13 years.
Futura Medical (LON: FUM) says results of the home user test of Eroxon and prototype Eroxon Intense were positive with an improvement on the previous phase 3 study for Eroxon. The study was over four weeks. Eroxon Intense gives a statistically significant greater sensorial effect over the current Eroxon® formulation. The participants had mild to moderate erectile dysfunction. This helps to target marketing at men under 60 years old with mid to moderate erectile dysfunction. Regulatory authorisation could be achieved is expected in the US and Europe by the end of the first half of 2026. The share price recovered 5.42% to 1.215p.
Metals One (LON: MET1) is focusing on creating a vertically integrated gold business in Sough Africa. It has converted $1.8m of loan notes to take a 30% stake in Lions Bay Resources, which is acquiring a cogeneration plant which may be reconfigured to include a gold concentrate roasting complex. It also plans to buy the assets of Vantage Goldfields, which has mining leases in the Barberton region that have a “historical resource inventory of 4.5 million ounces of gold”. Metals One has been selling its stakes in other AIM-quoted mining companies to raise cash to provide funds to help Lions Bay Resources to progress its deals. The Metals One share price is 4.26% ahead at 1.59p.
FALLERS
Frontier IP (LON: FIPP) investee company Alusid, where it owns 36.2%, has reached an agreement with Netherlands-based FRONT Materials and Tegelgroep Nederland for the distribution of tiles in the Netherlands. The wholesaler has distribution activities in adjoining countries. Initially, Mas floor tiles, using around 95% recycled material, will be stocked. Alusid is assessing the potential of a flotation. The Frontier IP share price slipped 11.85 to 11.25p.
SkinBioTherapeutics (LON: SBTX) shares continue to fall following the announcement at the end of last week that interim results will be delayed. The board investigation is continuing. This means that trading in the shares will be suspended on 1 April. Cash was £2.44m on 19 March. The share price declined 4% to 6p, having been as low as 5.25p.
Shares in Medpal AI (LON: MPAL) slid 9.48% to 2.625p following Friday evening’s placing and retail offer. The placing raised £527,000 at 2.5p/share and a retail offer could raise up to £200,000. The digital health company is entering the home blood testing market with the MedPal weight loss blood test.
Real-time video editing technology developer Blackbird (LON: BIRD) lost contracts and that led to a decline in revenues from £1.61m to £1.38m in 2025. Cash burn was £3.01m after a reduction in costs. There was £2.72m in the bank at the end of 2025 and £500,000 has been subsequently raised. User engagement of elevate.io is improving and the Winter Olympics should have provided a boost to use of the editing technology. The share price dipped 7.32% to 1.9p, which is just above the all-time low.
ImmuPharma (LON: IMM) has raised £469,000 from a retail offer at 6p/share, taking the total raised to £6.5m at 6p/share. ImmuPharma says that there is significant interest from potential licence partners in its autoimmune disease programme P140. The share price fell 7.84% to 4.7p.